There are some phrases which have become commonplace in pharma over the past few years. First, that data is the ‘new lifeblood’, able to make better, faster, more reliable decisions. But how many of us have really realized this benefit in a noticeable manner?
Merck & Co. is paying about $2.4 billion to acquire all outstanding shares of Antelliq Group, and is also assuming the digital technology company’s debt of $1.3 billion.
Novartis’ foray into digital technology intensified as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies.
U.S. regulators approved the first digital pill with an embedded sensor to track if patients are taking their medication properly, marking a significant step forward in the convergence of healthcare and technology.
It has long been thought that electronic data collection, also known as EDC, would be a time-saver when it comes to running clinical trials. But that may not be the case, according to a joint study released by Tufts University and Veeva Systems.
New Novartis Chief Executive Officer Vasant Narasimhan has a goal of saving 25 percent of clinical trial costs by using digital technology.